Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Einstein

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
European Urology|February 7, 2025
Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate CancerPraful Ravi, Lucia Kwak, Andres M Acosta, et al.
Frontiers in Sports and Active Living|November 10, 2025
Design of debunking the frailty-sarcopenia-ADT axis in metastatic prostate cancer with multicomponent exercise: the FIERCE trial protocolRebekah L Wilson, Anderson Vulczak, Alicia K Morgans, et al.
The Prostate|April 8, 2026
Castration Resistance Accelerates Prostate Cancer KineticsSheila Jonnatan, Luka Cavka, Angelo M De Marzo, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 12, 2024
Generation and Characterization of Ex Vivo Expanded Tumor-infiltrating Lymphocytes From Renal Cell Carcinoma Tumors for Adoptive Cell TherapyDavid J Einstein, Brian Halbert, Thomas Denize, et al.
Nature Communications|February 14, 2026
FOXJ1 mediates taxane resistance through regulation of microtubule dynamicsFang Xie, Ada Gjyrezi, Daniel Fein, et al.
Contemporary Clinical Trials|June 1, 2025
Exercise to enhance cardiovascular health among black men with prostate cancer with androgen deprivation therapy (the POWER trial): A study protocolDong-Woo Kang, Salvatore Ficarra, Rebekah L Wilson, et al.
Cancer Research|February 8, 2022
Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate CancerFen Ma, Seiji Arai, Keshan Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2025
Increased ErbB2 signaling is an early adaptation to androgen signaling inhibition and persists in castration resistant prostate cancerJude Owiredu, Betul Ersoy-Fazlioglu, Larysa Poluben, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor GenesCarla Calagua, Miriam Ficial, Caroline S Jansen, et al.
Cancer Research|November 22, 2022
Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor SignalingJesse C Patterson, Andreas Varkaris, Peter J P Croucher, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
European Urology|February 7, 2025
Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate CancerPraful Ravi, Lucia Kwak, Andres M Acosta, et al.
Frontiers in Sports and Active Living|November 10, 2025
Design of debunking the frailty-sarcopenia-ADT axis in metastatic prostate cancer with multicomponent exercise: the FIERCE trial protocolRebekah L Wilson, Anderson Vulczak, Alicia K Morgans, et al.
The Prostate|April 8, 2026
Castration Resistance Accelerates Prostate Cancer KineticsSheila Jonnatan, Luka Cavka, Angelo M De Marzo, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 12, 2024
Generation and Characterization of Ex Vivo Expanded Tumor-infiltrating Lymphocytes From Renal Cell Carcinoma Tumors for Adoptive Cell TherapyDavid J Einstein, Brian Halbert, Thomas Denize, et al.
Nature Communications|February 14, 2026
FOXJ1 mediates taxane resistance through regulation of microtubule dynamicsFang Xie, Ada Gjyrezi, Daniel Fein, et al.
Contemporary Clinical Trials|June 1, 2025
Exercise to enhance cardiovascular health among black men with prostate cancer with androgen deprivation therapy (the POWER trial): A study protocolDong-Woo Kang, Salvatore Ficarra, Rebekah L Wilson, et al.
Cancer Research|February 8, 2022
Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate CancerFen Ma, Seiji Arai, Keshan Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2025
Increased ErbB2 signaling is an early adaptation to androgen signaling inhibition and persists in castration resistant prostate cancerJude Owiredu, Betul Ersoy-Fazlioglu, Larysa Poluben, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor GenesCarla Calagua, Miriam Ficial, Caroline S Jansen, et al.
Cancer Research|November 22, 2022
Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor SignalingJesse C Patterson, Andreas Varkaris, Peter J P Croucher, et al.
Pageof 6